Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Member Features

Investigator Spotlight: Petros Grivas, MD, PhD

This month, Hoosier Cancer Research Network highlights University of Washington (UW) / Fred Hutchinson Cancer Research Center and Petros Grivas, MD, PhD, a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. In 2018, Dr. Grivas joined UW School of Medicine as an associate professor in the Department of Medicine and Clinical Director of the Genitourinary Cancers Program at UW and Fred Hutchinson Cancer Center. Read More

Investigator Spotlight: Rana R. McKay, MD

This month, Hoosier Cancer Research Network highlights Rana R. McKay, MD, a medical oncologist and researcher at UC San Diego Health. Dr. McKay specializes in treating people with urogenital cancers, including bladder, kidney, prostate, and testicular cancers, and leads a multi-disciplinary prostate cancer clinic. As an associate professor in the Department of Medicine, Dr. McKay instructs medical students, residents, and fellows at UC San Diego School of Medicine. She is a co-chair of HCRN’s Genitourinary Clinical Trial Working Group. Read More

Investigator Spotlight: Mylin Torres, MD

This month, Hoosier Cancer Research Network highlights Winship Cancer Institute of Emory University and Mylin Torres, MD, professor in the Department of Radiation Oncology, Emory University School of Medicine. Currently, Dr. Torres serves as co-leader of the Cancer Prevention and Control research program at Winship Cancer Institute while also serving as a radiation oncologist at the cancer center.

She is a member of HCRN’s Breast Cancer Clinical Trial Working Group and sponsor-investigator of HCRN BRE19-433, a multi-institutional Phase II study to evaluate efficacy and safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA). Read More

Investigator Spotlight: Andrew Poklepovic, MD

This month, Hoosier Cancer Research Network features Andrew S. Poklepovic, MD, in our investigator spotlight. Dr. Poklepovic serves as assistant professor in the Division of Hematology, Oncology and Palliative Care at the VCU Massey Cancer Center and is a Harrison Endowed Scholar at the VCU School of Medicine. He is also the medical director for the Massey Cancer Center Clinical Trials Office and an associate member of the Massey Cancer Center Developmental Therapeutics Program for the Department of Internal Medicine.

Read More

Investigator Spotlight: Ruth O’Regan MD

This month, Hoosier Cancer Research Network features our member institution University of Rochester Medical Center – Wilmot Cancer Institute and Ruth O’Regan, MD, the Charles A. Dewey Professor and Chair of Medicine at the University of Rochester Medical Center’s School of Medicine and Dentistry.

Dr. O’Regan is a medical oncologist with more than 25 years of experience in academic medicine. Her research interests are significantly focused on identifying mechanisms of resistance to breast cancer therapies, specifically endocrine-resistant and triple-negative breast cancers.

Read More

Investigator Spotlight: Coral Omene, MD, PhD

This month, Hoosier Cancer Research Network features our member institution Rutgers Cancer Institute of New Jersey and Coral Omene, MD, PhD, medical oncologist at Rutgers Cancer Institute and Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School.

Research Interests and Expertise:

Dr. Omene is a medical oncologist with a passion for women’s health who is dedicated to the care of treating and managing a diverse pool of breast cancer patients. She has devoted much of her research toward translating novel laboratory observations into discoveries to better care for breast cancer patients, with a particular focus on triple negative breast cancer (TNBC), which is known to be among the most aggressive breast cancers, with a poor prognosis, especially among African American women.

Read More

Investigator Spotlight: Hans Hammers, MD, PhD

This month, Hoosier Cancer Research Network features our member institution UT Southwestern Harold C. Simmons Comprehensive Cancer Center in Dallas, Texas, and Hans Hammers, MD, PhD, an associate professor of internal medicine in the Division of Hematology and Oncology at the UT Southwestern Medical School and the first Eugene P. Frenkel, M.D. Scholar in Clinical Medicine.

Read More

Investigator Spotlight: David Gallinson, DO

This month, Hoosier Cancer Research Network features our member institution Summit Health Cancer Center in Florham Park, New Jersey, and David Gallinson, DO, a medical oncologist.

Read More

Investigator Spotlight: Daniel M. Geynisman, MD

This month, Hoosier Cancer Research Network features our member institution Fox Chase Cancer Center, and Daniel M. Geynisman, MD, associate professor, Hematology/Oncology and a medical oncologist at Fox Chase Cancer Center.

Read More

Investigator Spotlight: Joshua F. Zeidner, MD

This month, Hoosier Cancer Research Network features our member institution University of North Carolina Lineberger Comprehensive Cancer Center and Joshua F. Zeidner, MD, associate professor of medicine, chief of leukemia research, and associate chief of research, hematology at UNC Lineberger.

Read More

Investigator Spotlight: Deepak Kilari, MD

This month, Hoosier Cancer Research Network features our member institution Froedtert & the Medical College of Wisconsin in Milwaukee, Wis., and Deepak Kilari, MD, a medical oncologist with specialization in genitourinary cancers.

Read More

Investigator Spotlight: Jian Li Campian, MD, PhD

This month, Hoosier Cancer Research Network features our member institution Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo., and Jian Li Campian, MD, PhD, a medical oncologist with specialization in neuro-oncology and immunotherapy.

Read More

Investigator Spotlight: Shilpa Gupta, MD

This month, Hoosier Cancer Research Network features our member institution Cleveland Clinic Cancer Center and medical oncologist Shilpa Gupta, MD. Dr. Gupta is a genitourinary oncologist and the leader of the bladder cancer program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio. She is also a member and co-chair elect of Hoosier Cancer Research Network’s Genitourinary Clinical Trial Working Group. Read More

Investigator Spotlight: Dwight Owen, MD, MS

This month, Hoosier Cancer Research Network features our member institution The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and medical oncologist Dwight Owen, MD, MS. Dr. Owen is a member of the Translational Therapeutics Program at the OSUCCC – James.

Read More

Investigator Spotlight: Nancy B. Davis, MD

This month, Hoosier Cancer Research Network features our member institution Vanderbilt-Ingram Cancer Center (VICC) in Nashville, Tenn., and Nancy B. Davis, MD, associate professor of medicine and VICC senior medical director for Cancer Care Network and Strategy, Division of Hematology/Oncology, Vanderbilt University Medical Center. Read More

Investigator Spotlight: Ulka Nitin Vaishampayan, MBBS, FAB

This month, Hoosier Cancer Research Network features our member institution, the University of Michigan Rogel Cancer Center, and Ulka Nitin Vaishampayan, MBBS, FAB, director of the phase I program at Rogel Cancer Center and a professor of internal medicine at the University of Michigan Medical School. Dr. Vaishampayan is leading an HCRN multi-institution study that will investigate pembrolizumab and lenvatinib in advanced/metastatic neuroendocrine prostate cancer. She is a site principal investigator on HCRN bladder cancer studies GU14-182 and GU15-262, and a co-investigator on the Big Ten Cancer Research Consortium kidney cancer study BTCRC-GU16-043. She is a member of the HCRN Genitourinary Clinical Trial Working Group. Read More

Investigator Spotlight: Benjamin Maughan, MD, PharmD

This month, Hoosier Cancer Research Network features our member, the Huntsman Cancer Institute at the University of Utah and Benjamin Maughan, MD, PharmD, assistant professor in the Division of Medical Oncology at Huntsman Cancer Institute, who specializes in genitourinary cancers.

Dr. Maughan is a site principal investigator for the HCRN bladder cancer studies GU16-257, GU16-287, and GU17-294, and a member of the HCRN Genitourinary Clinical Trial Working Group.

Research Interests and Expertise

Dr. Maughan’s research focus is on studying innate and acquired resistance mechanisms to therapy in genitourinary malignancies. In metastatic prostate cancer, he has studied how resistance pathways may play a role in expression of truncated androgen receptors (e.g., AR-V7 expression) and loss of tumor suppressors such as PTEN and Rb. More recently, Dr. Maughan has studied the resistance mechanisms toward immunotherapy in metastatic bladder, kidney, and prostate cancers in the context of novel immune therapy combinations for each of these cancers. For instance, one of his investigator-initiated clinical trials involves a combination of cancer vaccines (PSA and brachyury antigen directed) in combination with PD-L1 inhibition. Read More

Investigator Spotlight: Christos Kyriakopoulos, MD

This month, Hoosier Cancer Research Network features our member, the University of Wisconsin Carbone Cancer Center, and Christos Kyriakopoulos, MD, associate professor of medicine at the University of Wisconsin School of Medicine and Public Health, and a medical oncologist and researcher at UW Carbone Cancer Center.

Research Interests and Expertise

Dr. Kyriakopoulos is an institutional principal investigator for the HCRN study GU16-257, “Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing.” His research interests include clinical trials in prostate cancer, bladder cancer, and kidney cancer. He is particularly interested in imaging and immunotherapy studies in prostate cancer. He is also the study chair of the national trial EA8153, a study led by the ECOG-ACRIN Cancer Research Group in collaboration with the National Cancer Institute (NCI), that examines the role of chemo-hormonal therapy in patients with metastatic castration-resistant prostate cancer who have already received docetaxel. Read More

Investigator Spotlight: William P. Harris, MD

This month, Hoosier Cancer Research Network features our member Fred Hutchinson Cancer Research Center and William P. Harris, MD, associate professor of medicine for the University of Washington School of Medicine and a medical oncologist at Fred Hutch.

Research Interests and Expertise

Dr. Harris is a GI medical oncologist with a main research focus on hepatobiliary oncology. Specific areas of interest include interventional trials targeting therapy for patients with hepatocellular carcinoma and biliary tract cancers, and retrospective and prospective analyses assessing translational biomarkers and imaging features, which might predict response to systemic therapeutic interventions and combinations of local therapeutics and systemic therapy in treating liver tumors. Additional areas of involvement include medical education in medical oncology for pre-clinical medical school students, global health teaching, collaboration with the Uganda Cancer Institute, and involvement with patient advocacy foundations that optimize use of resources to facilitate research and patient care for patients with GI malignancies. Read More

Investigator Spotlight: Naomi Haas, MD

This month, Hoosier Cancer Research Network features our member Penn Medicine Abramson Cancer Center and Naomi Haas, MD, Director of Kidney and Prostate Cancer Clinical Research at Penn Medicine and Associate Professor of Medicine at the Hospital of University of Pennsylvania. Dr. Haas is an international expert in the conduct and design of adjuvant clinical trials for kidney cancer and a national expert in prostate and kidney cancer therapeutics. Dr. Haas is an institutional principal investigator for the HCRN study GU16-260, “Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma,” and participated in GU16-257, “Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing.”

Research Interests and Expertise

Dr. Haas’ research interests include early phase cancer clinical trials in kidney cancer, prostate cancer, and studying emerging treatment plans including those that use CAR T-Cell therapy, immune checkpoint inhibition, angiogenesis, and epigenetics. She also gained experience in retrotransposon, a type of genetic component that copies and pastes itself in different genomic locations by converting RNA back to DNA, through her early work in a basic science lab at Fox Chase Cancer Center. Read More

More News & Events →